NCT04954391

Brief Summary

Pulsed radiofrequency (PRF) neuromodulation / or ablation is an interventional pain management method. Clinical use of PRF for shoulder pain management generally focuses on the suprascapular nerve, what is considered a safe and superior to placebo and physiotherapy. We study the use of the PRF neuromodulation the suprascapular, axillary, and articular branches of the lateral pectoral nerve, as well as the effectiveness of this combined technique compared to the PRF of the suprascapular nerve alone

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
142

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 20, 2021

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 8, 2021

Completed
28 days until next milestone

Study Start

First participant enrolled

August 5, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2024

Completed
Last Updated

May 23, 2023

Status Verified

May 1, 2023

Enrollment Period

2.4 years

First QC Date

June 20, 2021

Last Update Submit

May 21, 2023

Conditions

Keywords

chronic shoulder painpulsed radiofrequencysuprascapular nerveaxillary nervelateral pectoral nerveshoulder arthroscopyrotator cuff injuryadhesive capsulitissubacromial impingementglenohumeral arthrosisacromioclavicular joint

Outcome Measures

Primary Outcomes (1)

  • SPADI value

    Scale value Shoulder Pain And Disability Index (SPADI) in points from minimum 0 to maximum 130, where a lower scores means a better outcome

    16 weeks from the time of the procedure

Secondary Outcomes (3)

  • Constant - Murley Shoulder Score

    16 weeks from the time of the procedure

  • Recovery in the functionality of the shoulder - DASH value

    16 weeks from the time of the procedure

  • EQ-5D-5L value

    16 weeks from the time of the procedure

Other Outcomes (3)

  • NSAIDs and opiates needs

    16 weeks from the time of the procedure

  • PRF complications

    16 weeks from the time of the procedure

  • Surgical treatment needs

    16 weeks from the time of the procedure

Study Arms (2)

PRF one nerve

ACTIVE COMPARATOR

Ultrasound guided PRF neuromodulation of suprascapular nerve and block axillary nerve, and articular branch of the lateral pectoral nerve with ropivacaine and dexamethasone

Procedure: Pulsed radiofrequency neuromodulation of the suprascapular nerve only

PRF three nerves

ACTIVE COMPARATOR

Ultrasound guided PRF neuromodulation of suprascapular, axillary nerves, and articular branch of the lateral pectoral nerve

Procedure: Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves

Interventions

PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg. Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg

Also known as: PRF one nerve
PRF one nerve

Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg

Also known as: PRF three nerves
PRF three nerves

Eligibility Criteria

Age18 Years - 99 Years
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Chronic pain (existing for more than three months at the time of examination) in the shoulder associated with the following pathology:
  • rotator cuff injury
  • adhesive capsulitis
  • arthrosis of the shoulder joint
  • arthrosis of the acromioclavicular joint
  • subacromial impingement syndrome
  • a history of arthroscopic surgery
  • Signed informed consent to participate in the study
  • Lack of indications for shoulder surgery
  • Age\> 18 years old 5 The positive effect of the test blockade of the suprascapular, axillary and lateral thoracic nerves with a local anesthetic (reduction of the pain level from the baseline according to NRS by at least 50%)

You may not qualify if:

  • Rotator cuff calcific tendinopathy
  • infectious arthritis
  • Instability of the shoulder joint
  • cervical radiculopathy
  • contraindications to local anesthetics
  • coagulopathy and anticoagulant therapy
  • pregnancy
  • oncology
  • the impossibility of subjective assessment of the level of pain and function of the joint

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saint Petersburg State University

Saint Petersburg, Russia

RECRUITING

Related Publications (3)

  • Korkmaz OK, Capaci K, Eyigor C, Eyigor S. Pulsed radiofrequency versus conventional transcutaneous electrical nerve stimulation in painful shoulder: a prospective, randomized study. Clin Rehabil. 2010 Nov;24(11):1000-8. doi: 10.1177/0269215510371417. Epub 2010 Aug 4.

  • Eyigor C, Eyigor S, Korkmaz OK, Uyar M. Intra-articular corticosteroid injections versus pulsed radiofrequency in painful shoulder: a prospective, randomized, single-blinded study. Clin J Pain. 2010 Jun;26(5):386-92. doi: 10.1097/AJP.0b013e3181cf5981.

  • Laumonerie P, Dalmas Y, Tibbo ME, Robert S, Faruch M, Chaynes P, Bonnevialle N, Mansat P. Sensory innervation of the human shoulder joint: the three bridges to break. J Shoulder Elbow Surg. 2020 Dec;29(12):e499-e507. doi: 10.1016/j.jse.2020.07.017. Epub 2020 Jul 23.

MeSH Terms

Conditions

Rotator Cuff InjuriesBursitisShoulder Impingement Syndrome

Condition Hierarchy (Ancestors)

RuptureWounds and InjuriesShoulder InjuriesTendon InjuriesJoint DiseasesMusculoskeletal Diseases

Study Officials

  • Konstantin Trukhin

    Saint Petersburg State University, Russia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Konstantin Trukhin

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
anesthesiologist

Study Record Dates

First Submitted

June 20, 2021

First Posted

July 8, 2021

Study Start

August 5, 2021

Primary Completion

December 30, 2023

Study Completion

April 30, 2024

Last Updated

May 23, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations